Literature DB >> 17191266

Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression.

B T Baune1, S Caliskan, D Todder.   

Abstract

OBJECTIVE: To investigate the effects of antidepressant therapy plus quetiapine on major depression, motor activity, daytime sleepiness and quality of sleep.
METHODS: Patients (N = 27) with major depressive disorder received a standard antidepressant treatment (Venlafaxine, Escitalopram) plus flexible dose of quetiapine. Patients' depression was monitored with HAM-D-21, motor activity was continuously measured with actigraphy and sleep parameters with the Pittsburgh Sleep Quality Index (PSQI) over 4 weeks.
RESULTS: Whereas depression, quality of sleep and daytime sleepiness showed a significant improvement over 4 weeks, change of daytime motor activity was significant only between the wash out period and the last 2 days of the study. Repeated measures of variance indicate an independent influence of quetiapine on improved depression, motor activity and sleep. While we found only a mild decrease of daytime sleepiness during the first week of treatment, the further decline of daytime sleepiness got significant after 2 weeks of treatment with quetiapine, even at high mean daily doses and despite the sedative effects of quetiapine.
CONCLUSIONS: Antidepressant treatment plus quetiapine is possibly a suitable treatment strategy to improve clinical depression, quality of sleep and motor activity. Future research is needed to understand the pharmacological interactions between antidepressants and quetiapine in major depression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17191266     DOI: 10.1002/hup.817

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  22 in total

1.  Agitated depression in substance dependence.

Authors:  Adam M Leventhal; Joel Gelernter; David Oslin; Raymond F Anton; Lindsay A Farrer; Henry R Kranzler
Journal:  Drug Alcohol Depend       Date:  2011-01-31       Impact factor: 4.492

2.  Quetiapine in primary insomnia: a pilot study.

Authors:  Michael H Wiegand; Florentina Landry; Torsten Brückner; Corina Pohl; Zdenko Veselý; Thomas Jahn
Journal:  Psychopharmacology (Berl)       Date:  2007-10-06       Impact factor: 4.530

3.  Computational Analysis of Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic Neurotransmitter and Stress Hormone Systems.

Authors:  Mariam B Camacho; Warut D Vijitbenjaronk; Thomas J Anastasio
Journal:  Front Pharmacol       Date:  2019-10-25       Impact factor: 5.810

4.  Quetiapine dosage across diagnostic categories.

Authors:  Yasser Khazaal; Anne Chatton; Riaz Khan; Daniele Zullino
Journal:  Psychiatr Q       Date:  2009-01-14

Review 5.  Therapeutic options for treatment-resistant depression.

Authors:  Richard C Shelton; Olawale Osuntokun; Alexandra N Heinloth; Sara A Corya
Journal:  CNS Drugs       Date:  2010-02       Impact factor: 5.749

Review 6.  Novel targets for antidepressant therapies.

Authors:  Paul E Holtzheimer; Charles B Nemeroff
Journal:  Curr Psychiatry Rep       Date:  2008-12       Impact factor: 5.285

7.  Effects of quetiapine on sleep architecture in patients with unipolar or bipolar depression.

Authors:  Laura Gedge; Lauren Lazowski; David Murray; Ruzica Jokic; Roumen Milev
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

Review 8.  Ambulatory assessment.

Authors:  Timothy J Trull; Ulrich Ebner-Priemer
Journal:  Annu Rev Clin Psychol       Date:  2012-11-13       Impact factor: 18.561

Review 9.  Utility of atypical antipsychotics in the treatment of resistant unipolar depression.

Authors:  Charles DeBattista; Jessica Hawkins
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  New developments in the management of major depressive disorder and generalized anxiety disorder: role of quetiapine.

Authors:  Bernhard T Baune
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.